Good arguments against using all-cause mortality,
Post# of 148185
Specifically, though, in this trial, two points speak directly to the op pieces concerns:
1) CD-12 really is an ICU trial - as noted, most aren't, and
2) Leronlimab will reduce SAEs (and their sequelae) vs. SOC